SeraCare Expands Genetic Portfolio with New ACCURUN Product
Product News Apr 16, 2014
SeraCare Life Sciences, a provider of high quality biological materials that help optimize diagnostic performance, reliability and repeatability across the IVD lifecycle, has announced the launch of its new ACCURUN® 611 product, a robust product that demonstrates consistent performance over time. This reference material is designed to support detection of the Factor V Leiden mutation and the Factor II gene variant, as well as mutations in the Methlyenetetrahydrofolate reductase (MTHFR) gene that are associated with significant health problems.
ACCURUN® 611 meets the needs of a broad range of molecular lab applications by providing heterozygous, mutant, or wild type scores for Factor II, Factor V, and MTHFR. It is ready-to-use genomic DNA manufactured from immortalized Peripheral Blood Mononuclear Cells (PBMCs) derived from human samples. Mutations were confirmed by a variety of commercial SNP genotyping assays, providing a robust challenge for all mutations in only two vials.
"ACCURUN® 611 is the first product on the market for this application that uses human-derived materials that closely resemble the target samples and provide a better monitor of the detection process," said Russell Garlick, Ph.D., Chief Scientific Officer at SeraCare. "This product is an important addition to our genetic offerings and reflects our commitment to empowering researchers with the tools they need to address today's diagnostic challenges."
SeraCare's new ACCURUN® 611 product is available immediately worldwide.